Advair Diskus Powder
Product Images NDC 50090-4310

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Advair Diskus (NDC 50090-4310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Advair Diskus Spl Graphic 01)

Chemical structure of fluticasone propionate, the active ingredient in ADVAIR DISKUS (fluticasone propionate and salmeterol). The diagram depicts the molecular framework with labeled atoms and stereochemistry.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Advair Diskus Spl Graphic 02)

Chemical structure diagram showing two molecular structures, identified as active ingredients fluticasone propionate and salmeterol in the ADVAIR DISKUS inhalation powder formulation.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 03)

A line graph depicting percent change in FEV1 over 12 weeks plus endpoint for ADVAIR DISKUS 100/50 twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. Data points are shown weekly with corresponding subject numbers listed below the x-axis. The graph compares lung function changes across treatments over time.*

FDA Label Image

S:\project Files\a\advair Diskus Nda 021077\figures\advair-diskus-spl-graphic-04.jpg (Advair Diskus Spl Graphic 04)

Line graph showing percentage change in FEV1 over 12 hours for ADVAIR DISKUS 100/50, salmeterol 50 mcg, fluticasone propionate 100 mcg, and placebo groups. ADVAIR DISKUS and salmeterol show higher peak improvements compared to fluticasone propionate and placebo.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 05)

A line graph showing the percent change in FEV1 relative to day 1 baseline over a 12-hour period for different treatment groups. The treatments compared include ADVAIR DISKUS 100/50 twice daily, Salmeterol 50 mcg once daily, Fluticasone propionate 100 mcg twice daily, and placebo. The graph tracks changes from baseline at day 1 and week 12 across hours 0 to 12.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 06)

A line chart showing the percentage change in FEV1 over 24 weeks comparing ADVAIR DISKUS 250/50, Salmeterol 50 mcg, and placebo groups. The x-axis represents weeks, and the y-axis represents percentage change in FEV1. ADVAIR DISKUS shows higher improvement compared to Salmeterol and placebo.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 07)

A line graph showing the percentage change in FEV1 over 24 weeks comparing ADVAIR DISKUS 250/50, fluticasone propionate 250 mcg, and placebo. The x-axis represents time in weeks, and the y-axis shows percent change in FEV1. Data points for each treatment group show trends and endpoint values over the study duration.*

FDA Label Image

Figure A (Advair Diskus Spl Graphic 08)

Illustration of an ADVAIR DISKUS inhaler device for respiratory delivery of fluticasone propionate and salmeterol powder. The image labels key parts including the outer case, mouthpiece, lever, thumb grip, and dose counter. The label shows a strength of 100/50 micrograms per actuation.*

FDA Label Image

Figure B (Advair Diskus Spl Graphic 09)

An instructional illustration showing two hands holding and sliding an ADVAIR DISKUS inhaler, a device delivering fluticasone propionate and salmeterol powder for respiratory inhalation. The image demonstrates the proper technique for activating or opening the inhaler by sliding its purple component.*

FDA Label Image

Figure C (Advair Diskus Spl Graphic 10)

An instructional illustration showing a hand holding a purple ADVAIR DISKUS inhaler device with an arrow indicating the direction to slide or open the device, demonstrating how to prepare it for use.*

FDA Label Image

Figure D (Advair Diskus Spl Graphic 11)

An illustration showing a woman holding and preparing to use an ADVAIR DISKUS inhaler for respiratory powder inhalation. The image demonstrates the inhalation process for administering fluticasone propionate and salmeterol powder via the inhaler device.*

FDA Label Image

Figure E (Advair Diskus Spl Graphic 12)

An illustration showing a woman holding and using a purple ADVAIR DISKUS inhaler to inhale medication. The image demonstrates the inhalation process for respiratory powder delivery.*

FDA Label Image

Figure F (Advair Diskus Spl Graphic 13)

Illustration showing hands holding an Advair Diskus inhaler, demonstrating the inhaler being opened or primed by sliding the lever in the direction indicated by an arrow to prepare for inhalation.*

FDA Label Image

Figure G (Advair Diskus Spl Graphic 14)

An illustrated instructional diagram showing a woman rinsing her mouth with water over a sink, with a cup of water placed nearby. This image likely depicts a recommended post-inhalation mouth rinsing step associated with respiratory powder inhaler use.*

FDA Label Image

Figure H (Advair Diskus Spl Graphic 15)

ADVAIR DISKUS 100/50 inhalation powder device showing a purple dry powder inhaler with a round white label identifying the dosage strength as 100 mcg fluticasone propionate / 50 mcg salmeterol. The device includes a dose counter displaying the number 5 and is labeled for respiratory inhalation use. The label indicates 60 blisters of medication.*

FDA Label Image

Label Image (Lbl500904310)

The packaging label for ADVAIR DISKUS 100 MCG/50 MCG inhalation powder by A-S Medication Solutions. It details that each blister contains 100 mcg of fluticasone propionate and 72.5 mcg of salmeterol xinafoate, equivalent to 50 mcg salmeterol base with lactose. The label includes storage instructions, device information, barcode, and distributor details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.